|
|
|
|
|
|
|
|
|
|
| Keith Elliston, Genstruct |
|
Keith Elliston, is Co-Founder, President and Chief Executive Officer of Genstruct, Inc. He is an experienced entrepreneur and intrapreneur who has dedicated his career to the development of leading-edge technology for drug discovery. Dr. Elliston spent over 10 years with Merck Research Laboratories, where he served as the director of bioinformatics, and the scientific director of the Merck Gene Index project. He then joined Bayer Pharmaceuticals where he founded their global genomics and bioinformatics efforts, and was the section head of Genomics and the worldwide head of Bioinformatics. In 1997, Dr. Elliston joined Gene Logic as chief scientific officer and pioneered the development and application of molecular profiling to drug discovery. He was responsible for the development and management of six pharmaceutical research partnerships representing over $350 million in potential revenues. In 1999, Dr. Elliston founded Viaken Systems, where he was chairman, president and CEO.
Dr. Elliston has been an advisor to Oak Investment Partners, Atlas Ventures and other biotechnology venture capital groups, and has participated in the early stage development of a number of successful biotech companies. Dr. Elliston received an M.S. in genetics from the University of Minnesota, and a Ph.D. in molecular genetics from Rutgers University.
|
|
Harnessing the Power of Systems Biology – Delivering Mechanism-of-Action and Biomarkers in Drug Development
Keith Elliston, Genstruct
Dexter Pratt, Bill Ladd, Toby Segaran, Justin Sun, Charlie Lieu and Keith Elliston. Genstruct Inc. Cambridge, MA, 02140
Systems biology offers new conceptual and computational tools for integrative analyses of complex clinical data sets. These tools allow researchers to break through cognitive barriers caused by the magnitude of molecular profiling information, and help us systematically elucidate and represent new biological insights. Using a systems biology approach, we have developed an integrated technology platform and methodologies that enable the investigation and identification of disease mechanisms, compound efficacies and toxicities. Panomics analyses of biological responses over time are used to map the trajectory of activated molecular pathways, and computable models are created to define molecular mechanisms.
We will present the methods and technology used to model scientific knowledge, generate specific mechanistic hypotheses through automated reasoning, and build computable Causal System Models. These models define the mechanisms underlying diseases, compound efficacies and toxic effects, and provide a map of the biological system to enable the identification of candidate biomarkers. Biomarkers can then be evaluated for their performance in noninvasive monitoring of the progression of disease, the mechanism of compound efficacy as well as the onset and reversal of toxicity.
|
|
|
|
|
|
|
|
|
